Haemonetics Corporation (HAE) - 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 27, 2025 (Fiscal 2026)
Business Overview: A global medical technology company operating in three segments: Plasma, Blood Center, and Hospital. The company focuses on plasma collection, blood center processing, and hospital technologies including interventional cardiology and blood management.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 27, 2025 |
3 Months Ended Dec 28, 2024 |
9 Months Ended Dec 27, 2025 |
9 Months Ended Dec 28, 2024 |
|---|---|---|---|---|
| Net Revenues | $338,967 | $348,542 | $987,676 | $1,030,225 |
| Gross Profit | $202,386 | $193,547 | $589,374 | $555,908 |
| Gross Margin | 59.7% | 55.5% | 59.7% | 54.0% |
| Operating Income | $67,396 | $59,029 | $179,759 | $150,482 |
| Operating Margin | 19.9% | 16.9% | 18.2% | 14.6% |
| Net Income | $44,740 | $37,494 | $117,455 | $109,698 |
| Diluted EPS | $0.95 | $0.74 | $2.46 | $2.14 |
| Cash & Equivalents | $363,367 (as of Dec 27, 2025) | |||
| Total Debt | $1,224,733 (as of Dec 27, 2025) | |||
| Operating Cash Flow (9mo) | $222,280 | $65,168 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 2.7% (QoQ) and 4.1% (YoY) for the nine months. The decline was driven by the divestiture of the Whole Blood product line (completed Jan 2025) and a customer transition at CSL Plasma in the Plasma segment. These were partially offset by growth in the Hospital segment, specifically the Hemostasis Management product line.
- Margin Expansion: Despite lower revenue, gross margin improved to 59.7% (from 54.0% YoY) due to a shift toward higher-margin products, pricing benefits, and reduced amortization of fair value inventory step-up from prior acquisitions.
- Operating Income Growth: Operating income increased 19.5% YoY for the nine months, driven by pricing, lower restructuring costs, and reduced amortization, partially offset by lower gains on asset sales.
- Impairment Charges: The company recorded a $9.3 million impairment charge for intangible assets related to the HAS viscoelastic diagnostic devices (acquired from HemoAssay) due to lower revenue projections.
- Segment Performance:
- Plasma: Revenue down 3.6% YoY (9mo) due to CSL transition.
- Blood Center: Revenue down 19.6% YoY (9mo) primarily due to the Whole Blood divestiture.
- Hospital: Revenue up 2.9% YoY (9mo) driven by Blood Management Technologies.
Guidance, Outlook, and Risks
- Acquisition Activity: Subsequent to the reporting period (Jan 9, 2026), Haemonetics acquired Vivasure Medical Limited for $116.4 million gross upfront consideration to expand its interventional cardiology portfolio. The deal includes up to $98.9 million in contingent consideration.
- Share Repurchases: The company has a $500 million authorization (through April 2028). As of Dec 27, 2025, $425 million remained available. In Q4, the company repurchased $25 million of stock under a Rule 10b5-1 plan.
- Restructuring: A new "Market and Regional Alignment Initiative" was approved in May 2025 to improve operational performance. Cumulative charges under this initiative were $5.5 million as of Dec 27, 2025.
- Debt Maturities: $300 million of 0.0% convertible senior notes mature on March 1, 2026. The company expects to settle this via cash on hand and revolving credit facility borrowings.
- Legal Proceedings:
- Patent Litigation: The company is involved in patent disputes with Terumo BCT and Fresenius Kabi regarding donor-centric blood plasma collection patents. The company filed complaints alleging infringement.
- Settlement: A patent litigation matter with Philips regarding OpSens technology was settled in Q2 2026 with an immaterial loss contingency.
- Forward-Looking Risks: Risks include regulatory approvals (FDA/CE Mark), foreign currency fluctuations, supply chain disruptions, and the realization of benefits from recent acquisitions.
Investor Verification Checklist
- Debt Refinancing: Verify the company's plan to refinance or repay the $300 million convertible notes maturing in March 2026.
- Acquisition Integration: Monitor the integration and performance of the newly acquired Vivasure Medical Limited and the contingent consideration milestones.
- Customer Concentration: Assess the long-term impact of the CSL Plasma customer transition on the Plasma segment's revenue stability.
- Restructuring Costs: Track the total cost and timeline of the "Market and Regional Alignment Initiative" to ensure it aligns with projected savings.
- Patent Litigation Outcomes: Review the status of ongoing patent lawsuits against Terumo BCT and Fresenius Kabi, as outcomes could impact future revenue or incur significant legal costs.